Join
Live feed
·
PRReleasevia Quantisnow
Rigel Pharmaceuticals Inc. logo

Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

ByQuantisnow·Wall Street's wire, on your screen.
RIGL· Rigel Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RIGL (Rigel Pharmaceuticals Inc.) and more on Quantisnow.